in vivo News and Research

RSS

tRNA synthetases play unexpected and critical role in cancer metastasis

Studied for decades for their essential role in making proteins within cells, several amino acids known as tRNA synthetases were recently found to have an unexpected - and critical - additional role in cancer metastasis in a study conducted collaboratively in the labs of Karen Lounsbury, Ph.D., University of Vermont professor of pharmacology, and Christopher Francklyn, Ph.D., UVM professor of biochemistry.

5 Mar 2013

PsiOxus completes enrollment in MT-102 Phase II trial on cancer cachexia

PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, has completed patient enrollment for its Phase II clinical trial to study MT-102, a small molecule therapeutic for the treatment of cancer cachexia.

4 Mar 2013

Medical Adhesives for Reusable or Disposable Medical Devices

An interview with Robert Michaels, discussing the major challenges faced by engineers designing medical devices and the development of new medical adhesives.

From Master Bond Inc. 28 Feb 2013

Promyleocytic leukemia gene goes up significantly in post treatment of mTOR inhibitors

Glioblastoma, the most common and lethal form of brain tumor in adults, is challenging to treat because the tumors rapidly become resistant to therapy. As cancer researchers are learning more about the causes of tumor cell growth and drug resistance, they are discovering molecular pathways that might lead to new targeted therapies to potentially treat this deadly cancer.

27 Feb 2013

Loss of Dickopf-1 restores neurogenesis and memory in animal model

Loss of the molecule Dickopf-1 in the hippocampus in older animals increases neurogenesis, research shows.

26 Feb 2013

Marine-based active substances show promise against multiple myeloma

There is fierce competition in the ocean habitat. In order to survive there, marine organisms defend themselves against their rivals using an entire arsenal of chemical weapons. With the help of these substances they attack hostile cells, overcome their defence system and thus are interesting active substance candidates for cancer research.

22 Feb 2013

Antibody delivery system launched that works even in presence of additives

...

22 Feb 2013

CB2 receptors might serve as potential therapeutic targets for cerebral ischemia

A new study published in the March issue of The American Journal of Pathology suggests that cortical type 2 cannabinoid (CB2) receptors might serve as potential therapeutic targets for cerebral ischemia.

22 Feb 2013

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) “auriclosene” (pronounced awr-rih-CLO-zeen) for the Company’s lead Aganocide® compound NVC-422.

21 Feb 2013

Daclatasvir has two primary modes of action against HCV

A study by researchers from Los Alamos National Laboratory and a multinational team reveals how daclatasvir, a direct-acting antiviral agent in development for the treatment of hepatitis C virus (HCV), targets one of its proteins and causes the fastest viral decline ever seen with anti-HCV drugs - within 12 hours of treatment.

21 Feb 2013

New study reveals how control of brain blood flow develops with age

A new study by Columbia Engineering researchers finds that the infant brain does not control its blood flow in the same way as the adult brain. The paper, which the scientists say could change the way researchers study brain development in infants and children, is published in the February 18 Early Online edition of Proceedings of the National Academy of Sciences (PNAS).

19 Feb 2013

Data from Eleven Biotherapeutics' EBI-005 preclinical study on ocular diseases

Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics, has published preclinical data in Proceedings of the National Academy of Sciences (PNAS) showing beneficial effects of EBI-005, the first rationally-designed topically administered IL-1 protein for the treatment of ocular diseases.

19 Feb 2013

MILabs VECTor/CT installed by Molecular Imaging Center Antwerp (MICA) in Belgium

MILabs B.V. is pleased to announce that the Molecular Imaging Center Antwerp (MICA) in Belgium has installed a MILabs VECTor/CT to enhance their portfolio of pre-clinical nuclear oncology and neurology imaging and research capabilities.

18 Feb 2013

Study describes pharmacological action of TZDs directly on pancreas

A scientific study published on the journal Diabetes, edited by the American Diabetes Association, describes for the first time the pharmacological action of thiazolidinediones (TZDs) —anti-diabetic drugs— directly on pancreas, the organ which produces insulin.

18 Feb 2013

New materials mimic mussel adhesive proteins for three medical applications

When it comes to sticking power under wet conditions, marine mussels are hard to beat. They can adhere to virtually all inorganic and organic surfaces, sustaining their tenacious bonds in saltwater, including turbulent tidal environments.

18 Feb 2013

Third Rock Ventures announces formation of Jounce Therapeutics

Third Rock Ventures, LLC today announced the formation of Jounce Therapeutics, Inc. with a $47 million Series A financing of the company. Jounce is focused on the discovery and development of first-in-class cancer immunotherapies designed to harness the patient's immune system to seek out and attack cancerous cells and tumors.

15 Feb 2013

Researchers identify new way to influence the vital serotonin signaling system

An interdisciplinary team of researchers from the University of Texas Medical Branch at Galveston and the University of Houston has found a new way to influence the vital serotonin signaling system - possibly leading to more effective medications with fewer side effects.

14 Feb 2013

Researchers describe novel antiviral property of cholesterol-25-hydroxylase

A team of UCLA-led researchers has identified a protein with broad virus-fighting properties that potentially could be used as a weapon against deadly human pathogenic viruses such as HIV, Ebola, Rift Valley Fever, Nipah and others designated "priority pathogens" for national biosecurity purposes by the National Institute of Allergy and Infectious Disease.

13 Feb 2013

Familial psychosis risk linked to prefrontal dopamine dysfunction

People at familial risk for psychosis have attenuated dopamine stress modulation in the ventromedial prefrontal cortex, according to a recent in vivo imaging study.

8 Feb 2013

Milk thistle constituent shows promising skin protection properties

Silibinin, a key component of milk thistle seeds, can help protect against skin damage caused by ultraviolet B radiation, show study findings published in Molecular Carcinogenesis.

8 Feb 2013